DNMT3A and peripheral arterial disease: Büttner et al. recently found that 88% of CHIP mutations (primarily in DNMT3A and TET2) present in the blood of patients with peripheral artery disease (PAD) were also present in atherosclerotic lesions, and that several patients also had these mutations in arterial collaterals, perivascular fat, and subcutaneous tissue [84].